[CD5-positive B lymphocytes and antinuclear antibodies]. 1998

T Fucíková, and J Cermáková, and H Marecková, and I Janatková, and O Krystůfková, and J Bartůnková, and T Poch
Ustav klinické imunologie 1, LF UK, Praha.

BACKGROUND The production of natural autoantibodies incl. antinuclear antibodies (ANA) is ascribed to lymphocytes which have a CD5 molecule on their surface. The role of CD5 positive B lymphocytes in the induction of autoimmunity is obscure so far. The authors focused their attention on the incidence of antinuclear antibodies (AA) in subjects with different diseases and sought a relationship with the ratio of CD5 positive B lymphocytes in the peripheral blood stream. RESULTS CD5 positive lymphocytes were assessed on a flow cytometer using monoclonal anti CD5 and anti CD19 antibodies. Antinuclear antibodies are detected by indirect fluorescence on a substrate of human leucocytes and HEP-2 cells. In a group of 134 subjects the authors did not provide evidence of a direct relationship between the relative number of CD5 positive B lymphocytes in the peripheral blood stream and the presence of ANA (IgG, IgA, IgM), not even in 33 patients with autoimmune diseases. In 86 patients the authors revealed that antinuclear antibodies type IgM predominate in patients with repeated respiratory infections. In systemic diseases the isotype IgG predominates (p = 0.01). After immunosuppressive treatment with a favourable clinical effect the ANA isotype IgG disappears and isotype IgM is found more frequently. The incidence of the ANA isotype IgM is significantly higher in healthy subjects aged over 60 years than in younger subjects (12.5%/6.1%, p = 0.06), and more frequent in women (p = 0.05). CONCLUSIONS The presence of antinuclear antibodies is not associated with the amount of CD5 positive B lymphocyte in the peripheral blood stream.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000974 Antibodies, Antinuclear Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease. Anti-DNA Antibodies,Antibodies, Anti-DNA,Antinuclear Antibodies,Antinuclear Autoantibodies,Antinuclear Autoantibody,Antinuclear Factors,Antinuclear Antibody,Antinuclear Factor,Anti DNA Antibodies,Antibody, Antinuclear,Autoantibody, Antinuclear,Factor, Antinuclear
D016175 B-Lymphocyte Subsets A classification of B-lymphocytes based on structurally or functionally different populations of cells. B-Cell Subsets,Tumor-Infiltrating B Cells,Tumor-Infiltrating B Lymphocytes,B Effector 1 Cells,B Effector 2 Cells,B-1 Cells,B-1 Lymphocytes,B-2 Lymphocytes,B-Lymphocytes, Effector,B1 Lymphocytes,B2 Lymphocytes,Be1 Cells,Be2 Cells,Effector B Cells,B 1 Cells,B 1 Lymphocytes,B 2 Lymphocytes,B Cell Subsets,B Cell, Tumor-Infiltrating,B Lymphocyte Subsets,B Lymphocyte, Tumor-Infiltrating,B-1 Cell,B-1 Lymphocyte,B-2 Lymphocyte,B-Cell Subset,B-Lymphocyte Subset,B-Lymphocyte, Effector,B1 Lymphocyte,B2 Lymphocyte,Be1 Cell,Be2 Cell,Cell, B-1,Cell, Be1,Cell, Be2,Effector B Cell,Effector B-Lymphocyte,Effector B-Lymphocytes,Lymphocyte, B-1,Lymphocyte, B-2,Lymphocyte, B1,Lymphocyte, B2,Tumor Infiltrating B Cells,Tumor Infiltrating B Lymphocytes,Tumor-Infiltrating B Cell,Tumor-Infiltrating B Lymphocyte
D018956 CD5 Antigens Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156) Antigens, CD5,CD5 Antigen,Leu-1 Antigen,T1 Antigen,Antigen, CD5,Leu 1 Antigen

Related Publications

T Fucíková, and J Cermáková, and H Marecková, and I Janatková, and O Krystůfková, and J Bartůnková, and T Poch
August 2021, Diagnostics (Basel, Switzerland),
T Fucíková, and J Cermáková, and H Marecková, and I Janatková, and O Krystůfková, and J Bartůnková, and T Poch
July 1990, The Journal of rheumatology,
T Fucíková, and J Cermáková, and H Marecková, and I Janatková, and O Krystůfková, and J Bartůnková, and T Poch
November 1989, Immunology today,
T Fucíková, and J Cermáková, and H Marecková, and I Janatková, and O Krystůfková, and J Bartůnková, and T Poch
July 1991, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
T Fucíková, and J Cermáková, and H Marecková, and I Janatková, and O Krystůfková, and J Bartůnková, and T Poch
February 1991, Clinical and experimental immunology,
T Fucíková, and J Cermáková, and H Marecková, and I Janatková, and O Krystůfková, and J Bartůnková, and T Poch
January 1988, Anticancer research,
T Fucíková, and J Cermáková, and H Marecková, and I Janatková, and O Krystůfková, and J Bartůnková, and T Poch
January 1990, International immunology,
T Fucíková, and J Cermáková, and H Marecková, and I Janatková, and O Krystůfková, and J Bartůnková, and T Poch
January 1989, Annual review of immunology,
T Fucíková, and J Cermáková, and H Marecková, and I Janatková, and O Krystůfková, and J Bartůnková, and T Poch
January 1995, Rivista europea per le scienze mediche e farmacologiche = European review for medical and pharmacological sciences = Revue europeenne pour les sciences medicales et pharmacologiques,
T Fucíková, and J Cermáková, and H Marecková, and I Janatková, and O Krystůfková, and J Bartůnková, and T Poch
April 1992, Annals of the rheumatic diseases,
Copied contents to your clipboard!